{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:39:45Z","timestamp":1792118385986,"version":"4.4.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>A majority of men with prostate cancer have low-grade cancer and an excellent prognosis after radical prostatectomy. Hypogonadism and associated symptoms impair quality of life in prostate cancer survivors. Many guidelines, citing a lack of randomized clinical trials showing safety and efficacy of testosterone replacement therapy (TRT), consider a history of prostate cancer a contraindication for TRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the short-term safety and efficacy of TRT in prostate cancer survivors with symptomatic hypogonadism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This randomized, placebo-controlled, double-blind, parallel-group, phase 2 trial was conducted at 2 academic medical centers in men 40 years and older with organ-confined, low-grade prostate cancer (Gleason score of 6 [3\u2009+\u20093] or 7 [3\u2009+\u20094]). Participants had undetectable prostate-specific antigen (PSA) for at least 2 years after radical prostatectomy, a mean of 2 testosterone levels less than 275 ng\/dL, and low libido, erectile dysfunction, or fatigue. Patients were allocated using concealed, block randomization, with stratification for age (40-60 years or &amp;amp;gt;60 years) and phosphodiesterase-5 inhibitor (PDE5I) use. The first participant was randomized on May 13, 2019, and the last study visit was completed on May 16, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Testosterone cypionate, 100 mg, or placebo intramuscularly weekly for 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary efficacy outcome was sexual activity. Secondary outcomes included sexual desire, erectile function, well-being, body composition, aerobic capacity, and physical function. The safety outcome was biochemical recurrence (PSA\u2009\u2265\u20090.2 ng\/mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 136 men were randomized, 68 to receive testosterone cypionate, 100 mg, and 68 to receive placebo, and 125 men completed the study. Groups were similar at baseline (mean [SD] age, 68.6 [6.5] years; 52 [38%] had a Gleason score of 6; and 84 [62%] had a Gleason score of 7). No participant in either group experienced biochemical recurrence. TRT significantly increased sexual activity more than placebo, adjusted for PDE5I use and age (between-group difference, 0.91 daily events [95% CI, 0.56-1.26];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). TRT increased sexual desire and prostate cancer quality-of-life sexual domain score, and decreased negative affect more than placebo. Erectile function did not change. TRT significantly improved body composition, loaded stair-climbing power, and peak aerobic performance (VO\n                      <jats:sub>2<\/jats:sub>\n                      peak) compared with placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this randomized clinical trial, TRT for 12 weeks in men treated with radical prostatectomy for low-grade prostate cancer significantly improved sexual activity, sexual desire, well-being, body composition, physical function, and aerobic performance compared to placebo without biochemical recurrence. The trial was neither long enough nor large enough to evaluate clinical recurrence or long-term safety; this proof-of-concept trial was essential for rationalizing a larger, long-term study. These findings do not apply to men with high-grade prostate cancer or those treated with androgen deprivation therapy or radiation therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT03716739\">NCT03716739<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.1343","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:30:46Z","timestamp":1778513446000},"page":"805","source":"Crossref","is-referenced-by-count":8,"title":["Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism"],"prefix":"10.1001","volume":"186","author":[{"given":"Shalender","family":"Bhasin","sequence":"first","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L.","family":"Burnett","sequence":"additional","affiliation":[{"name":"Brady Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Gagliano-Juc\u00e1","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Storer","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Reid","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili Valentine","family":"Shang","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Privat","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan S.","family":"Chandra","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Weiss","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusnie","family":"Memish-Beleva","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lam","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[{"name":"Department of Urology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol M.","family":"Pencina","sequence":"additional","affiliation":[{"name":"Research Program in Men\u2019s Health, Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"ioi260020r2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide.","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"issue":"1","key":"ioi260020r3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.urology.2007.10.055","article-title":"Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.","volume":"72","author":"Hernandez","year":"2008","journal-title":"Urology"},{"issue":"2","key":"ioi260020r4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cncr.10657","article-title":"Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.","volume":"95","author":"D\u2019Amico","year":"2002","journal-title":"Cancer"},{"key":"ioi260020r5","first-page":"37S","article-title":"Prevalence of hypogonadism in low-risk prostate cancer survivors.","volume":"33","author":"Agrawal","year":"2016","journal-title":"Fed Pract"},{"issue":"2","key":"ioi260020r6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41443-019-0116-0","article-title":"Pre- and post-radical prostatectomy testosterone levels in prostate cancer patients.","volume":"31","author":"Lumbiganon","year":"2019","journal-title":"Int J Impot Res"},{"key":"ioi260020r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2025.06.001","article-title":"High prevalence of low testosterone in men undergoing urologic surgery: results of a prospective study.","author":"Panken","year":"2025","journal-title":"Asian J Urol"},{"issue":"6","key":"ioi260020r8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.7326\/0003-4819-148-6-200803180-00209","article-title":"Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.","volume":"148","author":"Wilt","year":"2008","journal-title":"Ann Intern Med"},{"issue":"3","key":"ioi260020r9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0090-4295(99)00172-7","article-title":"Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor.","volume":"54","author":"Litwin","year":"1999","journal-title":"Urology"},{"issue":"1","key":"ioi260020r10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S0022-5347(05)68052-4","article-title":"Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE.","volume":"163","author":"Walsh","year":"2000","journal-title":"J Urol"},{"issue":"7","key":"ioi260020r11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men.","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"ioi260020r12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1210\/clinem\/dgad484","article-title":"Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism.","volume":"109","author":"Pencina","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"ioi260020r13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1210\/clinem\/dgae026","article-title":"Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy.","volume":"109","author":"Bhasin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"ioi260020r14","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society Clinical Practice Guideline.","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ioi260020r15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA Guideline.","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"ioi260020r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ijir.2008.41","article-title":"ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males.","volume":"21","author":"Wang","year":"2009","journal-title":"Int J Impot Res"},{"issue":"5","key":"ioi260020r17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5694\/mja16.00448","article-title":"Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations.","volume":"205","author":"Yeap","year":"2016","journal-title":"Med J Aust"},{"issue":"2","key":"ioi260020r18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/cen.14633","article-title":"Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism.","volume":"96","author":"Jayasena","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"ioi260020r19","first-page":"232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"ioi260020r20","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/1097-0142(196711)20:11<1871::AID-CNCR2820201112>3.0.CO;2-D","article-title":"Response of men with advanced prostatic carcinoma to exogenous administration of testosterone.","volume":"20","author":"Prout","year":"1967","journal-title":"Cancer"},{"issue":"2","key":"ioi260020r21","first-page":"131","article-title":"Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer.","volume":"69","author":"Golabek","year":"2016","journal-title":"Cent European J Urol"},{"issue":"5","key":"ioi260020r22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"issue":"16","key":"ioi260020r23","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/dji240","article-title":"Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study.","volume":"97","author":"Swerdlow","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"ioi260020r24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djm323","article-title":"Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.","volume":"100","author":"Roddam","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"ioi260020r25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/jsm.12768","article-title":"Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.","volume":"12","author":"Kaplan","year":"2015","journal-title":"J Sex Med"},{"issue":"10","key":"ioi260020r26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.urolonc.2019.06.007","article-title":"Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis.","volume":"37","author":"Kardoust Parizi","year":"2019","journal-title":"Urol Oncol"},{"issue":"5","key":"ioi260020r27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.juro.2015.05.084","article-title":"Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer.","volume":"194","author":"Pastuszak","year":"2015","journal-title":"J Urol"},{"issue":"1","key":"ioi260020r28","first-page":"27","article-title":"Testosterone therapy in men after radical prostatectomy for low-intermediate organ-confined prostate cancer.","volume":"213","author":"Flores","year":"2025","journal-title":"J Urol"},{"issue":"1","key":"ioi260020r29","first-page":"S26","article-title":"Testosterone therapy in men with prostate cancer: scientific and ethical considerations.","volume":"189","author":"Morgentaler","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"ioi260020r30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2013.08.015","article-title":"A new era of testosterone and prostate cancer: from physiology to clinical implications.","volume":"65","author":"Khera","year":"2014","journal-title":"Eur Urol"},{"issue":"12","key":"ioi260020r31","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1210\/jc.2019-00806","article-title":"Prostate-specific antigen levels during testosterone treatment of hypogonadal older men: data from a controlled trial.","volume":"104","author":"Cunningham","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ioi260020r32","first-page":"407","article-title":"Testosterone replacement increases fat-free mass and muscle size in hypogonadal men.","volume":"82","author":"Bhasin","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ioi260020r33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/andr.13299","article-title":"Testosterone replacement in prostate cancer survivors with testosterone deficiency: study protocol of a randomized controlled trial.","volume":"11","author":"Valderr\u00e1bano","year":"2023","journal-title":"Andrology"},{"key":"ioi260020r34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ahj.2021.11.016","article-title":"Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study.","volume":"245","author":"Bhasin","year":"2022","journal-title":"Am Heart J"},{"issue":"6","key":"ioi260020r35","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/gerona\/glz167","article-title":"The stair climb power test as an efficacy outcome in randomized trials of function promoting therapies in older men.","volume":"75","author":"Gagliano-Juc\u00e1","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"ioi260020r36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1210\/jc.2016-2935","article-title":"Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe.","volume":"102","author":"Travison","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ioi260020r37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/andr.13310","article-title":"Reference intervals for free testosterone in adult men measured using a standardized equilibrium dialysis procedure.","volume":"11","author":"Jasuja","year":"2023","journal-title":"Andrology"},{"issue":"3","key":"ioi260020r38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/19466315.2015.1043395","article-title":"The FDA\u2019s Final Rule on Expedited Safety Reporting: statistical considerations.","volume":"7","author":"Wittes","year":"2015","journal-title":"Stat Biopharm Res"},{"issue":"8","key":"ioi260020r39","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1210\/jc.2016-1645","article-title":"Testosterone treatment and sexual function in older men with low testosterone levels.","volume":"101","author":"Cunningham","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"ioi260020r40","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jsxm.2018.05.008","article-title":"Validity and clinically meaningful changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: results from the testosterone trials.","volume":"15","author":"Wang","year":"2018","journal-title":"J Sex Med"},{"issue":"12","key":"ioi260020r41","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors.","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"ioi260020r43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ijir.2009.7","article-title":"A population-based survey of sexual activity, sexual problems and associated help-seeking behavior patterns in mature adults in the United States of America.","volume":"21","author":"Laumann","year":"2009","journal-title":"Int J Impot Res"},{"issue":"8","key":"ioi260020r44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJMoa067423","article-title":"A study of sexuality and health among older adults in the United States.","volume":"357","author":"Lindau","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"ioi260020r45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3833","article-title":"Trends in frequency of sexual activity and number of sexual partners among adults aged 18 to 44 years in the US, 2000-2018.","volume":"3","author":"Ueda","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"ioi260020r46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/00224499.2017.1293603","article-title":"The effects of subjective age and aging attitudes on mid- to late-life sexuality.","volume":"55","author":"Estill","year":"2018","journal-title":"J Sex Res"},{"issue":"4","key":"ioi260020r47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/geronb\/gbr058","article-title":"Sexual frequency decline from midlife to later life.","volume":"66","author":"Karraker","year":"2011","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"issue":"6","key":"ioi260020r48","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","article-title":"Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis.","volume":"3","author":"Hudson","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"5","key":"ioi260020r50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186","article-title":"Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training.","volume":"5","author":"Swank","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"11","key":"ioi260020r51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa011858","article-title":"Exercise capacity and mortality among men referred for exercise testing.","volume":"346","author":"Myers","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"ioi260020r52","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/gerona\/glr100","article-title":"Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation.","volume":"66","author":"Travison","year":"2011","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"ioi260020r53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10508-018-1256-x","article-title":"Sexual activity and sexual satisfaction among older adults in four European countries.","volume":"48","author":"Tr\u00e6en","year":"2019","journal-title":"Arch Sex Behav"},{"key":"ioi260020r42","volume-title":"Sexual Health, Human Rights and the Law","author":"Organization","year":"2015"},{"key":"ioi260020r49"},{"key":"ioi260020r1","unstructured":"American Cancer Society. Key statistics for prostate cancer. Accessed September 5, 2025. https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2848537\/jamainternal_bhasin_2026_oi_260020_1781812065.47899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:01:03Z","timestamp":1783350063000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2848537"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.1343","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}